Catalyst Wire Dossier Catalyst Wire Dossier
CLINICAL_TRIALS ClinicalTrials.gov record update

A Multicenter Study Conducted to Evaluate the Performance of the LumiraDx SARS-CoV-2 & FLU A/B Test, and LumiraDx SARS-CoV-2 & RSV Test at Point of Care Testing Sites

This page presents selected fields from the linked source record. It does not add a medical interpretation.

Open original source record ↗

Record identity and dates

Source
ClinicalTrials.gov
Source record ID
NCT05268939
Title field or adapter rule
protocolSection.identificationModule.officialTitle
Ingested At
2026-04-28T10:39:38.108266+00:00
Published At
2023-08-14T00:00:00+00:00
Record Updated At
2023-08-14
Timestamp Basis
source retrieval time was not retained by the feed adapter
Date limitation
source retrieval time was not retained by the feed adapter

Fields recorded by this source

protocolSection.conditionsModule.conditions
["COVID-19", "Influenza A", "Influenza Type B", "RSV Infection"]
protocolSection.statusModule.lastUpdatePostDateStruct.date
"2023-08-14"
protocolSection.identificationModule.nctId
"NCT05268939"
protocolSection.identificationModule.officialTitle
"A Multicenter Study Conducted to Evaluate the Performance of the LumiraDx SARS-CoV-2 \u0026 FLU A/B Test, and LumiraDx SARS-CoV-2 \u0026 RSV Test at Point of Care Testing Sites"
protocolSection.statusModule.overallStatus
"COMPLETED"
protocolSection.designModule.phases
["NA"]
protocolSection.statusModule.resultsFirstPostDateStruct.date
""

Study condition terms

  • COVID-19 (protocolSection.conditionsModule.conditions)
  • Influenza A (protocolSection.conditionsModule.conditions)
  • Influenza Type B (protocolSection.conditionsModule.conditions)
  • RSV Infection (protocolSection.conditionsModule.conditions)

Intervention details are not present in the imported fields for this record. No drug-condition relationship is inferred from co-listing.

This index keeps the source fields it imported; it may not contain the complete original record. Verify wording and context in the linked source.